Syncona Ltd made two profitable asset sales during its first financial quarter ended 30 June enabling it to invest in a start-up cell therapy company and provide follow-on financing for its clinical-stage gene therapy company Autolus Therapeutics Plc which is listed on the US Nasdaq market.
